Cisplatin-loaded polymeric nanoparticles: Characterization and potential exploitation for the treatment of non-small cell lung carcinoma

Acta Biomaterialia

Volumn 18, Issue , 2015, Pages 68-76

  Shi, Chunshan ^a,c   Yu, Haiyang ^b   Sun, Dejun ^a   Ma, Lili ^b   Tang, Zhaohui ^b   Xiao, Qiusheng ^c   Chen, Xuesi ^b  

^a JILIN UNIVERSITY   (China)

^b CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^c No 208 Hospital of PLA   (China)

Author keywords

Cisplatin; Glutamic acid; Metabolism; Nanoparticle; NSCLC

Indexed keywords

BIOACTIVITY; BIOLOGICAL ORGANS; DEGRADATION; ETHYLENE; ETHYLENE GLYCOL; LANTHANUM COMPOUNDS; METABOLISM; NANOPARTICLES; POLYOLS; SOLUTIONS; TUMORS;

CIS-PLATIN; CISPLATIN; GLUTAMIC ACID; LEWIS LUNG CARCINOMATA; MEDIAN SURVIVAL TIME; METHOXY POLY(ETHYLENE GLYCOL); METHOXYPOLYETHYLENE GLYCOL; NON-SMALL-CELL LUNG CARCINOMATA; POLY(LGLUTAMIC ACID); POLY-L-GLUTAMIC ACIDS;

AMINO ACIDS;

CISPLATIN; DEOXYGUANOSINE PHOSPHATE; ESTER DERIVATIVE; NANOPARTICLE; PLATINUM; POLY(LEVO GLUTAMIC ACID)G METHOXY POLY(ETHYLENE GLYCOL 5K)NANOPARTICLE; POLYGLUTAMIC ACID; POLYMER; UNCLASSIFIED DRUG; 2'-DEOXYGUANOSINE 5'-PHOSPHATE; MACROGOL DERIVATIVE; METHOXYPOLY(ETHYLENE GLYCOL)-BLOCK-POLY(GLUTAMIC ACID); SOLUTION AND SOLUBILITY;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CANCER SURVIVAL; CHELATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; LEWIS CARCINOMA; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; UPTAKE ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DRUG EFFECTS; ENDOCYTOSIS; HELA CELL LINE; HEMOLYSIS; HYDRODYNAMICS; IC50; KIDNEY; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; METABOLISM; PHOTON CORRELATION SPECTROSCOPY; RABBIT; SIZE EXCLUSION CHROMATOGRAPHY; SOLUTION AND SOLUBILITY; SURVIVAL;

MUS;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, GEL; CISPLATIN; DEOXYGUANINE NUCLEOTIDES; DYNAMIC LIGHT SCATTERING; ENDOCYTOSIS; HELA CELLS; HEMOLYSIS; HUMANS; HYDRODYNAMICS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; KIDNEY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLUTAMIC ACID; RABBITS; SOLUTIONS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL ANALYSIS;

EID: 84927052626     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2015.02.009     Document Type: Article

References (33)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. R. Siegel, C. DeSantis, K. Virgo, K. Stein, A. Mariotto, and T. Smith Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220 241
3. M.B. Beasley, E. Brambilla, and W.D. Travis The 2004 World Health Organization classification of lung tumors Semin Roentgenol 40 2005 90 97
4. R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney, and A. Vlahiotis Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 2006 4539 4544
5. W. Pao, and N. Girard New driver mutations in non-small-cell lung cancer Lancet Oncol 12 2011 175 180
6. A. Paramanathan, B. Solomon, M. Collins, M. Franco, S. Kofoed, and H. Francis Patients treated with platinum-doublet chemotherapy for advanced non-small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation Clin Lung Cancer 14 2013 508 512
7. J. Goffin, C. Lacchetti, P.M. Ellis, Y.C. Ung, W.K. Evans Evidence CCOP First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer a systematic review J Thorac Oncol 5 2010 260 274
8. E.R. Jamieson, and S.J. Lippard Structure, recognition, and processing of cisplatin-DNA adducts Chem Rev 99 1999 2467 2498
9. D. Zhou, H. Xiao, F. Meng, X. Li, Y. Li, and X. Jing A polymer-(tandem drugs) conjugate for enhanced cancer treatment Adv Healthc Mater 2 2013 822 827
10. S. Tanida, T. Mizoshita, K. Ozeki, H. Tsukamoto, T. Kamiya, and H. Kataoka Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment Int J Surg Oncol 2012 2012 8
11. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am J Med Sci 334 2007 115 124
12. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, and T. Honda Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br J Cancer 93 2005 678 687
13. S.S. Beladi Mousavi, M. Hossainzadeh, A. Khanzadeh, F. Hayati, M. Beladi Mousavi, and A.A. Zeraati Protective effect of forced hydration with isotonic saline, potassium chloride and magnesium sulfate on cisplatin nephrotoxicity: an initial evaluation Asia Pac J Med Toxicol 2 2013 136 139
14. K.P. Morgan, L.W. Buie, and S.W. Savage The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy Ann Pharmacother 46 2012 276 281
15. A. Ghorbani, B. Omidvar, and A. Parsi Protective effect of selenium on cisplatin induced nephrotoxicity: a double-blind controlled randomized clinical trial J Nephropathol 2 2013 129 134
16. Y. Kidera, H. Kawakami, T. Sakiyama, K. Okamoto, K. Tanaka, and M. Takeda Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection PLoS One 9 2014 e101902
17. H. Cabral, and K. Kataoka Progress of drug-loaded polymeric micelles into clinical studies J Control Release 190 2014 465 476
18. H. Soo Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, and B. Itty Ipe Renal clearance of quantum dots Nat Biotech 25 2007 1165 1170
19. S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, and S.J. Lippard Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles Proc Natl Acad Sci USA 105 2008 17356 17361
20. J.V. Jokerst, T. Lobovkina, R.N. Zare, and S.S. Gambhir Nanoparticle PEGylation for imaging and therapy Nanomedicine 6 2011 715 728
21. A.Z. Wang, R. Langer, and O.C. Farokhzad Nanoparticle delivery of cancer drugs Annu Rev Med 63 2012 185 198
22. H. Yu, Z. Tang, D. Zhang, W. Song, Y. Zhang, and Y. Yang Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(l-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy J Control Release 2014 10.1016/j.jconrel.2014.12.022
23. Z. Ahmad, Z. Tang, A. Shah, S. Lv, D. Zhang, and Y. Zhang Cisplatin loaded methoxy poly (ethylene glycol)-block-poly (l-glutamic acid-co-l-phenylalanine) nanoparticles against human breast cancer cell Macromol Biosci 14 2014 1337 1345
24. Y. Huang, Z. Tang, X. Zhang, H. Yu, H. Sun, and X. Pang PH-triggered charge-reversal polypeptide nanoparticles for cisplatin delivery: preparation and in vitro evaluation Biomacromolecules 14 2013 2023 2032
25. Y. Li, G.H. Gao, and D.S. Lee Stimulus-sensitive polymeric nanoparticles and their applications as drug and gene carriers Adv Healthc Mater 2 2013 388 417
26. E.M. Dibbern, F.J.-J. Toublan, and K.S. Suslick Formation and characterization of polyglutamate core-shell microspheres J Am Chem Soc 128 2006 6540 6541
27. U. Warnke, C. Rappel, H. Meier, C. Kloft, M. Galanski, and C.G. Hartinger Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5′-monophosphate O6-N7 chelation ChemBioChem 5 2004 1543 1549
28. H. Xiao, G.T. Noble, J.F. Stefanick, R. Qi, T. Kiziltepe, and X. Jing Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo J Control Release 173 2014 11 17
29. L. Ren, X.-L. Huang, B. Zhang, L.-P. Sun, Q.-Q. Zhang, and M.-C. Tan Cisplatin-loaded Au-Au2S nanoparticles for potential cancer therapy: cytotoxicity, in vitro carcinogenicity, and cellular uptake J Biomed Mater Res A 85A 2008 787 796
30. F.A. Levi, W.J.M. Hrushesky, F. Halberg, T.R. Langevin, E. Haus, and B.J. Kennedy Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration Eur J Cancer Clin Oncol 18 1982 471 477
31. Y. Mizumura, Y. Matsumura, T. Hamaguchi, N. Nishiyama, K. Kataoka, and T. Kawaguchi Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity Cancer Sci 92 2001 328 336
32. B.A. Teicher, K. Menon, E. Alvarez, E. Galbreath, C. Shih, and M.M. Faul Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts Cancer Chemother Pharmacol 48 2001 473 480
33. L.A. Shuman Moss, S. Jensen-Taubman, D. Rubinstein, G. Viole, and W.G. Stetler-Stevenson Dietary intake of a plant phospholipid/lipid conjugate reduces lung cancer growth and tumor angiogenesis Carcinogenesis 35 2014 1556 1563